Genetisch onderzoek bij prostaatkanker: nieuwe ontwikkelingen

Translated title of the contribution: Genetic testing in patients with prostate cancer: new developments

Margreet G.E.M. Ausems*, Lambertus A.L.M. Kiemeney

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)

Abstract

At this moment, germline genetic testing is rarely requested in patients with prostate cancer. However, a breast cancer gene mutation is frequently detected in men with metastasized prostate cancer (mainly in BRCA2). In this paper we propose criteria for genetic testing in prostate cancer. Genetic test results may have major implications for relatives who may take appropriate measures to prevent cancer or diagnose it at an early stage. It may also have direct relevance for the treatment of the patient. It is time to set up a new workflow enabling treating physicians to order a DNA test (mainstreaming of genetic testing). It calls for close collaboration between clinical geneticists and treating physicians, and adequate education of urologists, oncologists and specialized nurses.

Translated title of the contributionGenetic testing in patients with prostate cancer: new developments
Original languageDutch
Pages (from-to)30-35
Number of pages6
JournalTijdschrift voor Urologie
Volume10
Issue number2-3
DOIs
Publication statusPublished - 1 Mar 2020

Keywords

  • BRCA2
  • germline
  • mainstreaming genetic testing
  • metastatic prostate cancer

Fingerprint

Dive into the research topics of 'Genetic testing in patients with prostate cancer: new developments'. Together they form a unique fingerprint.

Cite this